Advertisement

Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma

      Abstract

      A 73-year-old woman with metastatic vaginal mucosal melanoma that had progressed on ipilimumab and nivolumab experienced clinical and radiographic complete response to dual checkpoint inhibitor immunotherapy given in combination with high-dose plus low-dose radiation. General characteristics and treatment options in this disease are highlighted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ballo M.T.
        • et al.
        Combined-modality therapy for patients with regional nodal metastases from melanoma.
        Int. J. Radiat. Oncol. Biol. Phys. 2006; 64: 106-113
        • Lerner B.A.
        • et al.
        Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease.
        Oncology (Williston Park). 2017; 31: e23-e32
        • AJCC
        Cancer Staging Manual.
        8th ed. Springer International Publishing, Switzerland2017
        • Gershenwald J.E.
        • et al.
        Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
        CA Cancer J. Clin. 2017; 67: 472-492
        • Balch C.M.
        • et al.
        Final version of 2009 AJCC melanoma staging and classification.
        J. Clin. Oncol. 2009; 27: 6199-6206
        • Wohlmuth C.
        • et al.
        Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients.
        Am. J. Clin. Dermatol. 2020; 21: 285-295
        • Seifried S.
        • et al.
        Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases.
        Ann. Surg. Oncol. 2015; 22: 1959-1966
        • Piura B.
        Management of primary melanoma of the female urogenital tract.
        Lancet Oncol. 2008; 9: 973-981
        • Koh S.S.
        • Cassarino D.S.
        Immunohistochemical expression of p16 in melanocytic lesions: an updated review and meta-analysis.
        Arch. Pathol. Lab. Med. 2018; 142: 815-828
        • Milman T.
        • et al.
        Immunohistochemical profiling of conjunctival melanocytic intraepithelial lesions, including Sox10, Hmb45, Ki67, and P16.
        Am J. Ophthalmol. 2021 Feb; 222 (Epub 2020 Sep 28. PMID: 33002486): 148-156https://doi.org/10.1016/j.ajo.2020.09.033
        • Yde S.S.
        • et al.
        Mucosal melanoma: a literature review.
        Curr. Oncol. Rep. 2018; 20: 28
        • D’Angelo S.P.
        • et al.
        Efficacy and safety of nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis.
        J. Clin. Oncol. 2017; 35: 226-235
        • National Cancer Institute
        Surveillance, Epidemiology and End Results.
        (Available from:)
        • Chang A.E.
        • Karnell L.H.
        • Menck H.R.
        The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.
        Cancer. 1998; 83: 1664-1678
        • McLaughlin C.C.
        • et al.
        Incidence of noncutaneous melanomas in the U.S.
        Cancer. 2005; 103: 1000-1007
        • Gokaslan H.
        • et al.
        Primary malignant melanoma of the vagina: a case report and review of the current treatment options.
        Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 121: 243-248
        • Gadducci A.
        • et al.
        Melanoma of the lower genital tract: prognostic factors and treatment modalities.
        Gynecol. Oncol. 2018; 150: 180-189
        • Patrick R.J.
        • Fenske N.A.
        • Messina J.L.
        Primary mucosal melanoma.
        J. Am. Acad. Dermatol. 2007; 56: 828-834
        • Mihajlovic M.
        • et al.
        Primary mucosal melanomas: a comprehensive review.
        Int. J. Clin. Exp. Pathol. 2012; 5: 739-753
        • Cazenave H.
        • et al.
        Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families.
        Br. J. Dermatol. 2013; 169: 594-599
        • O’Regan K.
        • et al.
        Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence.
        Cancer Imaging. 2013; 13: 626-632
        • Garbe C.
        • et al.
        Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.
        Eur. J. Cancer. 2012; 48: 2375-2390
        • Leitao Jr., M.M.
        • et al.
        Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas.
        Int. J. Gynecol. Cancer. 2014; 24: S117-S122
        • Lian B.
        • et al.
        Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
        Clin. Cancer Res. 2013; 19: 4488-4498
        • Janco J.M.
        • et al.
        Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
        Gynecol. Oncol. 2013; 129: 533-537
        • Harting M.S.
        • Kim K.B.
        Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
        Melanoma Res. 2004; 14: 517-520
        • Pusceddu S.
        • et al.
        A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer.
        Crit. Rev. Oncol. Hematol. 2012; 81: 185-195
        • Sugiyama V.E.
        • Chan J.K.
        • Kapp D.S.
        Management of melanomas of the female genital tract.
        Curr. Opin. Oncol. 2008; 20: 565-569
        • Chapman P.B.
        • et al.
        Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
        N. Engl. J. Med. 2011; 364: 2507-2516
        • Hodi F.S.
        • et al.
        Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
        J. Clin. Oncol. 2013; 31: 3182-3190
        • Kalinsky K.
        • et al.
        A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607).
        Cancer. 2017; 123: 2688-2697
        • Marabondo S.
        • Kaufman H.L.
        High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
        Expert Opin. Drug Saf. 2017; 16: 1347-1357
        • Hodi F.S.
        • et al.
        Improved survival with ipilimumab in patients with metastatic melanoma.
        N. Engl. J. Med. 2010; 363: 711-723
        • Schadendorf D.
        • et al.
        Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma.
        J. Clin. Oncol. 2015; 33: 1889-1894
        • Del Vecchio M.
        • et al.
        Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
        Eur. J. Cancer. 2014; 50: 121-127
        • Postow M.A.
        • et al.
        Ipilimumab for patients with advanced mucosal melanoma.
        Oncologist. 2013; 18: 726-732
        • Moya-Plana A.
        • et al.
        Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
        Cancer Immunol. Immunother. 2019; 68: 1171-1178
        • Shoushtari A.N.
        • et al.
        The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
        Cancer. 2016; 122: 3354-3362
        • Topalian S.L.
        • et al.
        Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
        J. Clin. Oncol. 2014; 32: 1020-1030
        • Robert C.
        • et al.
        Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
        Lancet. 2014; 384: 1109-1117
        • Androutsopoulos G.
        • et al.
        Vaginal primary malignant melanoma: a rare and aggressive tumor.
        Case Rep. Obstet. Gynecol. 2013; 2013: 137908
        • Frumovitz M.
        • et al.
        Primary malignant melanoma of the vagina.
        Obstet. Gynecol. 2010; 116: 1358-1365
        • Karasawa K.
        • et al.
        Clinical trial of carbon ion radiotherapy for gynecological melanoma.
        J. Radiat. Res. 2014; 55: 343-350
        • Irvin Jr., W.P.
        • et al.
        Malignant melanoma of the vagina and locoregional control: radical surgery revisited.
        Gynecol. Oncol. 1998; 71: 476-480
        • Kirschner A.N.
        • et al.
        Treatment approach and outcomes of vaginal melanoma.
        Int. J. Gynecol. Cancer. 2013; 23: 1484-1489
        • Mole R.H.
        Whole body irradiation; radiobiology or medicine?.
        Br. J. Radiol. 1953; 26: 234-241
        • Lhuillier C.
        • et al.
        Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system.
        Genome Med. 2019; 11: 40
        • Patel R.R.
        • et al.
        Use of multi-site radiation therapy for systemic disease control.
        Int. J. Radiat. Oncol. Biol. Phys. 2021 Feb 1; 109 (Epub 2020 Aug 13. PMID: 32798606): 352-364https://doi.org/10.1016/j.ijrobp.2020.08.025
        • Barsoumian H.B.
        • et al.
        Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.
        J. Immunother. Cancer. 2020; : 8(2)
        • Ballo M.T.
        • Ang K.K.
        Radiation therapy for malignant melanoma.
        Surg. Clin. North Am. 2003; 83: 323-342
        • Overgaard J.
        The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study.
        Int. J. Radiat. Oncol. Biol. Phys. 1986; 12: 867-872
        • Bentzen S.M.
        • et al.
        Clinical radiobiology of malignant melanoma.
        Radiother. Oncol. 1989; 16: 169-182
        • Wang X.
        • et al.
        Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy.
        Cancer Res. 2017; 77: 839-850
        • Ridolfi L.
        • et al.
        Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
        J. Transl. Med. 2014; 12: 262
        • D’Andrea M.A.
        • Reddy G.K.
        Systemic antitumor effects and abscopal responses in melanoma patients receiving radiation therapy.
        Oncology. 2020; 98: 202-215
        • Theelen W.
        • et al.
        Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
        Lancet Respir. Med. 2020 Oct 20; (S2213-2600(20)30391-X; Epub ahead of print. Erratum in: Lancet Respir Med. 2021 Mar;9(3):e29. PMID: 33096027.)https://doi.org/10.1016/S2213-2600(20)30391-X
        • Ngwa W.
        • et al.
        Using immunotherapy to boost the abscopal effect.
        Nat. Rev. Cancer. 2018; 18: 313-322
        • Meng X.
        • et al.
        The role of radiation oncology in immuno-oncology.
        Oncologist. 2019; 24: S42-S52
        • Menon H.
        • et al.
        Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.
        J. Immunother. Cancer. 2019; 7: 237
        • Welsh J.W.
        • et al.
        Phase II trial of Ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses.
        Cancer Immunol Res. 2019; 7: 1903-1909